Rosalind Advisors, Inc. recently announced the acquisition of new stake in Trevi Therapeutics Inc. (NASDAQ:TRVI). The institutional investor has increased its shareholding in the Healthcare company by 14.38% to 2.5 million shares with purchase of 0.31 million shares. This fresh investment now brings its stake to 4.16% valued currently at $8.6 million. In addition, The Vanguard Group, Inc. raised its holdings by 0.12 million to 1.43 million shares.
With over 2.29 million Trevi Therapeutics Inc. (TRVI) shares trading Tuesday and a closing price of $2.40 on the day, the dollar volume was approximately $5.5 million. The shares have shown a positive half year performance of 12.15% and its price on 05/23/23 gained nearly 5.26%. Currently, there are 98.61M common shares owned by the public and among those 57.54M shares have been available to trade.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for TRVI have a consensus price objective of $7.33. The analysts have set the share’s price value over the next 12 months at a high of $9.00 and a low of $6.00. The average price target is 67.26% above its recent price level and an upside to the estimated low will see the stock gain 60.0% over that period. But an upside of 73.33% will see the stock hit the forecast high price target while median target price for the stock is $7.50.
Insiders at the company have transacted a total of 11 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 4 of these insider trades were purchases, accounting for 50,833 shares. Insider sales of the common stock occurred on 7 occasions, with total insider shares sold totaling 986,172 shares.
The top 3 mutual fund holders in Trevi Therapeutics Inc. are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Bridgeway Ultra Small Company Mar. Vanguard Total Stock Market ETF owns 1.07 million shares of the company’s stock, all valued at over $3.67 million. Vanguard Extended Market Index Fu bought 15674.0 shares to see its total holdings expand to 0.38 million shares valued at over $1.29 million and representing 0.63% of the shares outstanding. Bridgeway Ultra Small Company Mar bought 49100.0 shares to bring its total holdings to over 0.2 million shares at a value of $0.67 million. Bridgeway Ultra Small Company Mar now owns shares totaling to 0.33% of the shares outstanding.
Shares of Trevi Therapeutics Inc. (NASDAQ: TRVI) opened at $2.23, down -$0.05 from a prior closing price of $2.28. However, the script later moved the day high at 2.4800, up 5.26%. The company’s stock has a 5-day price change of -6.61% and 4.35% over the past three months. TRVI shares are trading 24.35% year to date (YTD), with the 12-month market performance up to 6.67% higher. It has a 12-month low price of $1.43 and touched a high of $4.68 over the same period. TRVI has an average intraday trading volume of 122.48K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -18.76%, 1.79%, and -0.16% respectively.
Institutional ownership of Trevi Therapeutics Inc. (NASDAQ: TRVI) shares accounts for 82.20% of the company’s 98.61M shares outstanding. Mutual fund holders own 3.42%, while other institutional holders and individual stakeholders account for 37.41% and 20.77% respectively.
It has a market capitalization of $141.19M and a beta (3y monthly) value of 0.77. The earnings-per-share (ttm) stands at -$0.47. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.39% over the week and 9.73% over the month.
Analysts forecast that Trevi Therapeutics Inc. (TRVI) will achieve an EPS of $The Travelers Companies, Inc. for the current quarter, $179.31 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Maravai LifeSciences Holdings, while analysts give the company a high EPS estimate of $Thomson Reuters Corp. Comparatively, EPS for the current quarter was $Trevi Therapeutics, Inc. a year ago. Earnings per share for the fiscal year are expected to increase by 69.60%, and -19.40% over the next financial year.
